Abstract | AIMS: METHODS:
PGB was titrated in 135 patients [73 men; 62 women, aged 18-76 (median 44 years) until one of the following occurred: ≥ 6 months' seizure freedom, ≥ 50% or < 50% seizure reduction over 6 months; PGB withdrawal because of adverse effects, lack of efficacy or both. RESULTS: Of the 135 patients, 14 (10.4%) became seizure-free for ≥ 6 months (median PGB dose 300 mg/day; range 75-600 mg). A ≥ 50% seizure reduction occurred in 33 (24.4%) patients; 20 (14.8%) had < 50% reduction. PGB was withdrawn in 68 (50.4%) (40 adverse effects, seven lack of efficacy and 21 both). Commonest problems resulting in withdrawal were sedation (n = 18), weight gain (n = 14) and ataxia (n = 9). There was a positive correlation between increasing dose and weight gain (r = 0.42, P = 0.045). CONCLUSIONS: Add-on PGB benefited 50% of patients, but only 10% achieved 6 months' seizure freedom. Adverse effects, most commonly sedation, dose-related weight gain and ataxia, led to drug discontinuation by 45%. Prospective audits of novel AEDs are a useful adjunct to randomized, controlled trials in managing epilepsy.
|
Authors | L J Stephen, P Parker, K Kelly, E A Wilson, V Leach, M J Brodie |
Journal | Acta neurologica Scandinavica
(Acta Neurol Scand)
Vol. 124
Issue 2
Pg. 142-5
(Aug 2011)
ISSN: 1600-0404 [Electronic] Denmark |
PMID | 21434875
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2011 John Wiley & Sons A/S. |
Chemical References |
- Anticonvulsants
- Pregabalin
- gamma-Aminobutyric Acid
|
Topics |
- Adolescent
- Adult
- Aged
- Anticonvulsants
(therapeutic use)
- Body Weight
(drug effects)
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Pregabalin
- Prospective Studies
- Seizures
(drug therapy)
- Substance Withdrawal Syndrome
(diagnosis, physiopathology)
- Treatment Outcome
- Young Adult
- gamma-Aminobutyric Acid
(adverse effects, analogs & derivatives, therapeutic use)
|